Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 579

1.

Psoriasis and Mental Health Workshop Report: Exploring the Links between Psychosocial Factors, Psoriasis, Neuroinflammation and Cardiovascular Disease Risk.

Kleyn CE, Talbot PS, Mehta NN, Sampogna F, Bundy C, Ashcroft DM, Kimball AB, Kerkhof PCM, Griffiths CEM, Valenzuela F, van der Walt JM, Aberra T, Puig L.

Acta Derm Venereol. 2019 Nov 19. doi: 10.2340/00015555-3375. [Epub ahead of print]

2.

Critical role of interleukin (IL)-17 in inflammatory and immune disorders: An updated review of the evidence focusing in controversies.

Ruiz de Morales JMG, Puig L, Daudén E, Cañete JD, Pablos JL, Martín AO, Juanatey CG, Adán A, Montalbán X, Borruel N, Ortí G, Martín EH, García-Vidal C, Morales CV, Vázquez VM, González-Gay MÁ.

Autoimmun Rev. 2019 Nov 14:102429. doi: 10.1016/j.autrev.2019.102429. [Epub ahead of print] Review.

PMID:
31734402
3.

Adjusted treatment COMPArisons between guSelkumab and uStekinumab for treatment of moderate-to-severe plaque psoriasis: the COMPASS Analysis.

Diels J, Thilakarathne P, Cameron C, McElligott S, Schubert A, Puig L.

Br J Dermatol. 2019 Oct 25. doi: 10.1111/bjd.18634. [Epub ahead of print]

PMID:
31652347
4.

Consistent response to guselkumab treatment between Hispanic and non-Hispanic patients with psoriasis: an analysis from VOYAGE 1 and VOYAGE 2.

Puig L, Wu JJ, Gooderham MJ, You Y, Shen YK, Randazzo B, Kerdel F.

J Dermatolog Treat. 2019 Oct 21:1-8. doi: 10.1080/09546634.2019.1679336. [Epub ahead of print]

PMID:
31613178
5.

The Patient-reported Disease Burden in Adults with Atopic Dermatitis: A Cross-sectional Study in Europe and Canada.

de Bruin-Weller M, Gadkari A, Auziere S, Simpson EL, Puig L, Barbarot S, Girolomoni G, Papp K, Pink AE, Saba G, Werfel T, Eckert L.

J Eur Acad Dermatol Venereol. 2019 Oct 6. doi: 10.1111/jdv.16003. [Epub ahead of print]

PMID:
31587373
6.

Body dysmorphic disorder in patients with acne: a multicentre study.

Marron SE, Miranda-Sivelo A, Tomas-Aragones L, Rodriguez-Cerdeira C, Tribo-Boixaro MJ, Garcia-Bustinduy M, Gracia-Cazaña T, Ros-Abarca S, Roe-Crespo E, Diaz-Díaz RM, Brufau-Redondo C, Martinez-Gonzalez MC, Guerra-Tapia A, González-Guerra E, Puig L.

J Eur Acad Dermatol Venereol. 2019 Sep 13. doi: 10.1111/jdv.15954. [Epub ahead of print]

PMID:
31515838
7.

Psoriasis precipitated by timolol eye drops. A series of eight cases.

Mir-Bonafé JF, Rozas-Muñoz E, Pedemonte-Sarrias E, Mir-Bonafé M, Mir-Bonafé JM, Piquero-Casals J, Puig L.

Australas J Dermatol. 2019 Sep 6. doi: 10.1111/ajd.13155. [Epub ahead of print]

PMID:
31489616
8.

Incidence of cardiovascular events among tildrakizumab-treated patients with moderate-to-severe plaque psoriasis: pooled data from three large randomised clinical trials.

Bissonnette R, Fernández-Peñas P, Puig L, Mendelsohn AM, Rozzo SJ, Menter A.

J Eur Acad Dermatol Venereol. 2019 Aug 12. doi: 10.1111/jdv.15866. [Epub ahead of print] No abstract available.

PMID:
31403725
9.

Significant weight loss improves and prevents psoriasis and psoriatic arthritis in obese patients: a Critically Appraised Topic and a call to action.

Puig L.

Br J Dermatol. 2019 Nov;181(5):884-885. doi: 10.1111/bjd.18322. Epub 2019 Aug 9. No abstract available.

PMID:
31399996
10.

Secukinumab demonstrates sustained efficacy in clearing skin and improving patient-reported outcomes in patients with moderate-to-severe psoriasis through 2 years of treatment: Results from the CLEAR study.

Thaçi D, Puig L, Reich K, Tsai TF, Tyring S, Kingo K, Ziv M, Pinter A, Vender R, Lacombe A, Xia S, Bhosekar V, Gilloteau I, Guana A, Blauvelt A.

J Am Acad Dermatol. 2019 Dec;81(6):1405-1409. doi: 10.1016/j.jaad.2019.04.045. Epub 2019 Aug 6. No abstract available.

11.

Treatment Appraisal Reports: Usefulness and Transparency.

Puig L, Carrascosa JM, Notario J, Belinchón I; en nombre del Grupo de Psoriasis de la AEDV.

Actas Dermosifiliogr. 2019 Jul 19. pii: S0001-7310(19)30250-9. doi: 10.1016/j.ad.2019.04.006. [Epub ahead of print] English, Spanish. No abstract available.

PMID:
31331616
13.

Biosimilars for the treatment of psoriasis.

Puig L, López-Ferrer A.

Expert Opin Biol Ther. 2019 Oct;19(10):993-1000. doi: 10.1080/14712598.2019.1636963. Epub 2019 Jul 1.

PMID:
31237786
14.

Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks.

Reich K, Warren RB, Iversen L, Puig L, Pau-Charles I, Igarashi A, Ohtsuki M, Falqués M, Harmut M, Rozzo S, Lebwohl MG, Cantrell W, Blauvelt A, Thaçi D.

Br J Dermatol. 2019 Jun 19. doi: 10.1111/bjd.18232. [Epub ahead of print]

PMID:
31218661
15.

Acute myocardial infarction in a patient with active actinic rectitis bleeding: Between the sword and the wall.

Manuel V, Steffen SP, Gaiotto FA, Puig LB.

J Card Surg. 2019 Jul;34(7):638-640. doi: 10.1111/jocs.14102. Epub 2019 Jun 18.

PMID:
31212360
16.

Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2.

Cork MJ, Eckert L, Simpson EL, Armstrong A, Barbarot S, Puig L, Girolomoni G, de Bruin-Weller M, Wollenberg A, Kataoka Y, Remitz A, Beissert S, Mastey V, Ardeleanu M, Chen Z, Gadkari A, Chao J.

J Dermatolog Treat. 2019 Jun 9:1-9. doi: 10.1080/09546634.2019.1612836. [Epub ahead of print]

17.

Patient-Reported Outcomes in Psoriasis Validated in Spain: PROs and Cons.

Puig L.

Actas Dermosifiliogr. 2019 Sep;110(7):518-519. doi: 10.1016/j.ad.2019.05.001. Epub 2019 Jun 5. English, Spanish. No abstract available.

PMID:
31176446
18.

Long-term efficacy and safety of brodalumab in the treatment of psoriasis: 120-week results from the randomized, double-blind, placebo- and active comparator-controlled phase 3 AMAGINE-2 trial.

Puig L, Lebwohl M, Bachelez H, Sobell J, Jacobson AA.

J Am Acad Dermatol. 2019 Jun 5. pii: S0190-9622(19)30899-0. doi: 10.1016/j.jaad.2019.05.095. [Epub ahead of print]

19.

Best-practice Indicators in Psoriatic Disease Care.

Helliwell PS, Favier G, Gladman DD, Soriano ER, Kirkham BW, Coates LC, Puig L, Boehncke WH, Thaçi D.

J Rheumatol Suppl. 2019 Jun;95:38-45. doi: 10.3899/jrheum.190120.

PMID:
31154403
20.

Secukinumab dosing optimization in patients with moderate-to-severe plaque psoriasis: results from the randomized, open-label OPTIMISE study.

Reich K, Puig L, Szepietowski JC, Paul C, Lacour JP, Tsianakas A, Sieder C, Rissler M, Pournara E, Orsenigo R.

Br J Dermatol. 2019 May 17. doi: 10.1111/bjd.18143. [Epub ahead of print]

PMID:
31102257
21.

Economic Impact of Etanercept in Patients with Psoriasis and Psoriatic Arthritis in Spain: A Systematic Review.

Puig L, Fernández-Freire LR, Burgos-Pol R, Gomez I, Peral C, Gomez S, Rebollo Laserna FJ.

Dermatol Ther (Heidelb). 2019 Sep;9(3):479-496. doi: 10.1007/s13555-019-0301-6. Epub 2019 May 6.

22.

Expert consensus on the persistence of biological treatments in moderate-to-severe psoriasis.

de la Cueva Dobao P, Notario J, Ferrándiz C, López Estebaranz JL, Alarcón I, Sulleiro S, Borrás J, Daudén E, Carrascosa JM, Sánchez Carazo JL, Monte Boquet E, Puig L.

J Eur Acad Dermatol Venereol. 2019 Jul;33(7):1214-1223. doi: 10.1111/jdv.15600. Epub 2019 Apr 29.

PMID:
31037770
23.

Development and Preliminary Validation of the HSQoL-24 Tool to Assess Quality of Life in Patients With Hidradenitis Suppurativa.

Marrón SE, Gómez-Barrera M, Tomás-Aragonés L, Díaz Díaz RM, Vilarrasa Rull E, Madrid Álvarez MB, Puig L.

Actas Dermosifiliogr. 2019 Sep;110(7):554-560. doi: 10.1016/j.ad.2019.02.002. Epub 2019 Apr 23. English, Spanish.

PMID:
31023484
24.

Carcinoma en Cuirasse.

Flores-Climente V, Rozas-Muñoz E, Puig L.

Actas Dermosifiliogr. 2019 Nov;110(9):e2. doi: 10.1016/j.ad.2018.01.019. Epub 2019 Apr 15. English, Spanish. No abstract available.

PMID:
31000136
25.

Quantification of Malassezia pachydermatis by real-time PCR in swabs from the external ear canal of dogs.

Puig L, Castellá G, Cabañes FJ.

J Vet Diagn Invest. 2019 May;31(3):440-447. doi: 10.1177/1040638719840686. Epub 2019 Apr 4.

PMID:
30943876
26.

Association Between Enthesitis and Health-related Quality of Life in Psoriatic Arthritis in Biologic-naive Patients from 2 Phase III Ustekinumab Trials.

McInnes IB, Puig L, Gottlieb AB, Ritchlin CT, Song M, You Y, Kafka S, Morgan GJ, Rahman P, Kavanaugh A; PSUMMIT 1 and 2 Study Groups.

J Rheumatol. 2019 Nov;46(11):1458-1461. doi: 10.3899/jrheum.180792. Epub 2019 Apr 1.

PMID:
30936281
27.

Guselkumab for the treatment of adults with moderate to severe plaque psoriasis.

Puig L.

Expert Rev Clin Immunol. 2019 Jun;15(6):589-597. doi: 10.1080/1744666X.2019.1601014. Epub 2019 Apr 12.

PMID:
30920855
28.

Pilonidal sinus disease: an intergluteal localization of hidradenitis suppurativa/acne inversa: a cross-sectional study among 2465 patients.

Benhadou F, Van der Zee HH, Pascual JC, Rigopoulos D, Katoulis A, Liakou AI, Daxhelet M, Romanelli M, Iannone M, Kinyó Á, Nikolakis G, Zouboulis CC, Dessinioti C, Zisimou C, Antoniou C, Alavi A, Mintoff D, Aquilina S, Matusiak L, Szepietowski JC, Sinclair R, Husein-ElAhmed H, von Laffert M, Revuz J, Danby B, Puig L, Theut Riis P, Jemec GBE, van van Straalen K, Wigny KMGJ, Del Marmol V, Guillem P.

Br J Dermatol. 2019 Mar 27. doi: 10.1111/bjd.17927. [Epub ahead of print]

PMID:
30919434
29.

Asymptomatic Exophytic Plaques on the Penis of a Patient With HIV Infection: Challenge.

Rozas-Muñoz E, Mir-Bonafé JF, Mozos A, Szafranska J, Puig L.

Am J Dermatopathol. 2019 Mar 11. doi: 10.1097/DAD.0000000000001345. [Epub ahead of print] No abstract available.

PMID:
30908294
30.

[Prevalence of ten Immune-mediated inflammatory diseases (IMID) in Spain].

Puig L, Ruiz de Morales JG, Dauden E, Andreu JL, Cervera R, Adán A, Marsal S, Escobar C, Hinojosa J, Palau J, Arraiza A, Casado P, Codesido M, Pascual C, Saldaña R, Gil Á.

Rev Esp Salud Publica. 2019 Mar 25;93. pii: e201903013. Spanish.

31.

Drug survival of conventional systemic and biologic therapies for moderate-to-severe psoriasis in clinical practice in Spain: prospective results from the SAHARA study.

Puig L, Carrascosa JM, Daudén E, Sulleiro S, Guisado C.

J Dermatolog Treat. 2019 Jun 20:1-8. doi: 10.1080/09546634.2019.1597244. [Epub ahead of print]

PMID:
30888880
32.

Effectiveness and safety of ustekinumab 90 mg in patients weighing 100 kg or less: a retrospective, observational, multicenter study.

Del Alcázar E, Ferran M, López-Ferrer A, Notario J, Vidal D, Riera J, Aparicio G, Gallardo F, Vilarrasa E, Alsina M, Puig L, Ferrándiz C, Carrascosa JM.

J Dermatolog Treat. 2019 Mar 18:1-5. doi: 10.1080/09546634.2019.1597245. [Epub ahead of print]

PMID:
30883242
33.

Successful intra-class switching among IL-17 antagonists: a multicentre, multinational, retrospective study.

Gasslitter I, Kirsten N, Augustin M, Torz K, Mrowietz U, Eyerich K, Puig L, Hoetzenecker W, Schütz-Bergmayr M, Weger W, Wolf P, Reider N, Ratzinger G, Papageorgiou K, Meier TO, Maul JT, Anzengruber F, Navarini AA.

Arch Dermatol Res. 2019 Jul;311(5):421-424. doi: 10.1007/s00403-019-01907-y. Epub 2019 Mar 16.

PMID:
30879102
34.

Incremental Cost per Responder (PASI-75, PASI-90 and PASI-100) Based on a Network Meta-Analysis of Biologic Therapies for Psoriasis: Spain 2018.

Puig L.

Actas Dermosifiliogr. 2019 Sep;110(7):517-518. doi: 10.1016/j.ad.2018.12.002. Epub 2019 Feb 18. English, Spanish. No abstract available.

PMID:
30791970
35.

Iceberg sign as a dermoscopic clue of actinic keratosis neglecta.

Mir-Bonafé JF, Rozas-Muñoz E, Dalmau J, Mir-Bonafé M, Iznardo H, García-Melendo C, Puig L.

J Eur Acad Dermatol Venereol. 2019 Jul;33(7):e254-e256. doi: 10.1111/jdv.15484. Epub 2019 Apr 15. No abstract available.

PMID:
30742717
36.

British Association of Dermatologists Biologic Interventions Register delivers: infliximab increases risk of serious infections.

Puig L.

Br J Dermatol. 2019 Feb;180(2):257-258. doi: 10.1111/bjd.17437. No abstract available.

PMID:
30714098
37.

Cutibacterium acnes in primary reverse shoulder arthroplasty: from skin to deep layers.

Torrens C, Marí R, Alier A, Puig L, Santana F, Corvec S.

J Shoulder Elbow Surg. 2019 May;28(5):839-846. doi: 10.1016/j.jse.2018.10.016. Epub 2019 Jan 24.

PMID:
30685278
38.

Genetic variation at the glycosaminoglycan metabolism pathway contributes to the risk of psoriatic arthritis but not psoriasis.

Aterido A, Cañete JD, Tornero J, Ferrándiz C, Pinto JA, Gratacós J, Queiró R, Montilla C, Torre-Alonso JC, Pérez-Venegas JJ, Fernández Nebro A, Muñoz-Fernández S, González CM, Roig D, Zarco P, Erra A, Rodríguez J, Castañeda S, Rubio E, Salvador G, Díaz-Torné C, Blanco R, Willisch Domínguez A, Mosquera JA, Vela P, Sánchez-Fernández SA, Corominas H, Ramírez J, de la Cueva P, Fonseca E, Fernández E, Puig L, Dauden E, Sánchez-Carazo JL, López-Estebaranz JL, Moreno D, Vanaclocha F, Herrera E, Blanco F, Fernández-Gutiérrez B, González A, Pérez-García C, Alperi-López M, Olivé Marques A, Martínez-Taboada V, González-Álvaro I, Sanmartí R, Tomás Roura C, García-Montero AC, Bonàs-Guarch S, Mercader JM, Torrents D, Codó L, Gelpí JL, López-Corbeto M, Pluma A, López-Lasanta M, Tortosa R, Palau N, Absher D, Myers R, Marsal S, Julià A.

Ann Rheum Dis. 2019 Mar;78(3). pii: e214158. doi: 10.1136/annrheumdis-2018-214158. Epub 2018 Dec 14.

PMID:
30552173
39.

The Pathogenesis of Extraintestinal Manifestations: Implications for IBD Research, Diagnosis, and Therapy.

Hedin CRH, Vavricka SR, Stagg AJ, Schoepfer A, Raine T, Puig L, Pleyer U, Navarini A, van der Meulen-de Jong AE, Maul J, Katsanos K, Kagramanova A, Greuter T, González-Lama Y, van Gaalen F, Ellul P, Burisch J, Bettenworth D, Becker MD, Bamias G, Rieder F.

J Crohns Colitis. 2019 Apr 26;13(5):541-554. doi: 10.1093/ecco-jcc/jjy191.

PMID:
30445584
40.

Vemurafenib-induced histiocytoid neutrophilic panniculitis simulating myeloid leukaemia cutis.

Richarz NA, Puig L, Pérez N, Cuadra-Urteaga J, Elez E, Fernández-Figueras MT.

Cancer Biol Ther. 2019;20(3):237-239. doi: 10.1080/15384047.2018.1529113. Epub 2018 Nov 14.

41.

The Effectiveness of Omalizumab Treatment in Real-Life is Lower in Patients with Chronic Urticaria Longer than 18 Months' Evolution and Prior Immunosuppressive Treatment.

Cubiró X, Spertino J, Rozas-Muñoz E, Serra-Baldrich E, Puig L.

Actas Dermosifiliogr. 2019 May;110(4):289-296. doi: 10.1016/j.ad.2018.09.009. Epub 2018 Oct 22. English, Spanish.

PMID:
30360885
42.

Initial results of ixekizumab efficacy and safety in real-world plaque psoriasis patients: a multicentre retrospective study.

Deza G, Notario J, Lopez-Ferrer A, Vilarrasa E, Ferran M, Del Alcazar E, Carrascosa JM, Corral M, Salleras M, Ribera M, Puig L, Pujol RM, Vidal D, Gallardo F.

J Eur Acad Dermatol Venereol. 2019 Mar;33(3):553-559. doi: 10.1111/jdv.15288. Epub 2018 Nov 13.

PMID:
30317679
43.

Reversibility of alexithymia with effective treatment of moderate-to-severe psoriasis: longitudinal data from EPIDEPSO.

Sampogna F, Puig L, Spuls P, Girolomoni G, Radtke MA, Kirby B, Brunori M, Bergmans P, Smirnov P, Rundle J, Castiglia A, Lavie F, Paul C.

Br J Dermatol. 2019 Feb;180(2):397-403. doi: 10.1111/bjd.17259. Epub 2018 Nov 26.

PMID:
30269346
44.

Non-pharmacological Effects in Switching Medication: The Nocebo Effect in Switching from Originator to Biosimilar Agent.

Kristensen LE, Alten R, Puig L, Philipp S, Kvien TK, Mangues MA, van den Hoogen F, Pavelka K, Vulto AG.

BioDrugs. 2018 Oct;32(5):397-404. doi: 10.1007/s40259-018-0306-1.

45.

Treatment of patients with plaque psoriasis with secukinumab in a real-life setting: a 52-week, multicenter, retrospective study in Spain.

Notario J, Deza G, Vilarrasa E, Valentí F, Muñoz C, Mollet J, Rocamora V, Carrascosa JM, Del Alcázar E, Alsina M, Vidal D, Puig L, López-Ferrer A, Riera J, Gallardo F, Ferran M.

J Dermatolog Treat. 2019 Aug;30(5):424-429. doi: 10.1080/09546634.2018.1528000. Epub 2018 Dec 3.

PMID:
30244618
46.

Benefit-risk profile of tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: pooled analysis across six clinical trials.

Strober BE, Gottlieb AB, van de Kerkhof PCM, Puig L, Bachelez H, Chouela E, Imafuku S, Thaçi D, Tan H, Valdez H, Gupta P, Kaur M, Frajzyngier V, Wolk R.

Br J Dermatol. 2019 Jan;180(1):67-75. doi: 10.1111/bjd.17149. Epub 2018 Oct 10.

PMID:
30188571
47.

Multitrait genome association analysis identifies new susceptibility genes for human anthropometric variation in the GCAT cohort.

Galván-Femenía I, Obón-Santacana M, Piñeyro D, Guindo-Martinez M, Duran X, Carreras A, Pluvinet R, Velasco J, Ramos L, Aussó S, Mercader JM, Puig L, Perucho M, Torrents D, Moreno V, Sumoy L, de Cid R.

J Med Genet. 2018 Nov;55(11):765-778. doi: 10.1136/jmedgenet-2018-105437. Epub 2018 Aug 30.

48.

Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.

Gordon KB, Strober B, Lebwohl M, Augustin M, Blauvelt A, Poulin Y, Papp KA, Sofen H, Puig L, Foley P, Ohtsuki M, Flack M, Geng Z, Gu Y, Valdes JM, Thompson EHZ, Bachelez H.

Lancet. 2018 Aug 25;392(10148):650-661. doi: 10.1016/S0140-6736(18)31713-6. Epub 2018 Aug 7.

PMID:
30097359
49.

Clinical and genetic differences between pustular psoriasis subtypes.

Twelves S, Mostafa A, Dand N, Burri E, Farkas K, Wilson R, Cooper HL, Irvine AD, Oon HH, Kingo K, Köks S, Mrowietz U, Puig L, Reynolds N, Tan ES, Tanew A, Torz K, Trattner H, Valentine M, Wahie S, Warren RB, Wright A, Bata-Csörgő Z, Szell M, Griffiths CEM, Burden AD, Choon SE, Smith CH, Barker JN, Navarini AA, Capon F.

J Allergy Clin Immunol. 2019 Mar;143(3):1021-1026. doi: 10.1016/j.jaci.2018.06.038. Epub 2018 Jul 21.

50.

Update on Topical Treatments for Psoriasis: The Role of Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam.

Puig L, Carretero G.

Actas Dermosifiliogr. 2019 Mar;110(2):115-123. doi: 10.1016/j.ad.2018.05.010. Epub 2018 Jul 19. English, Spanish.

PMID:
30031488

Supplemental Content

Support Center